Business Wire

Patient Safety Global Ministerial Summit Recognizes PSMF Founder Joe Kiani

Share

Global leaders in patient safety gathered for day one of the 11th Annual World Patient Safety, Science & Technology Summit to spotlight the most critical issues affecting patient safety. Held on the UC Irvine campus for the first time, the Patient Safety Movement Foundation’s (PSMF) annual meeting aims to build on progress made over the past decade toward eliminating preventable harm caused by medical error.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240906604830/en/

Patient Safety Movement Foundation Founder Joe Kiani is recognized by the Patient Safety Global Ministerial Summit at PSMF's annual World Patient Safety, Science & Technology Summit, which opened today. Dr. Mike Durkin, PSMF's board chair, presented the honor. (Photo: Business Wire)

After PSMF founder Joe Kiani provided the Summit’s opening remarks, the Patient Safety Global Ministerial Summit recognized him for his work in patient safety. “We recognize Joe Kiani with the deepest respect from the global community of families, experts, policymakers, and politicians in patient safety who have greatly benefited from his unwavering commitment to reducing avoidable harm to zero. His partnership with the World Health Organization, his contribution to the Global Patient Safety Action Plan, his outstanding leadership over many years at the Global Ministerial Summits on Patient Safety, and his drive and determination to ensure the ongoing advancement of science and technology across the global medical devices industries have ensured that our patients at every level and in every setting continue to benefit from his latest advances to reduce avoidable harm. The healthcare world is a safer environment because of his dedication, and both patients and healthcare workers will continue to reap the benefits of his excellence for decades to come.”

“I’m honored,” stated Joe Kiani. “The Patient Safety Global Ministerial Summit, the World Health Organization, and Dr. Tedros Adhanom Ghebreyesus have played a leading role in making patient safety a priority around the world. I believe that if we all work together, we have the tools and know-how to create a safer healthcare system for all. To get to zero, we have to implement evidence-based practices, and we need our board members and hospital C-suites demanding their implementation. There is great momentum, and we cannot stop until we reach ZERO preventable harm in our hospitals.”

Since their inception in 2016, the Global Ministerial Summits on Patient Safety have succeeded in raising awareness, as well as creating and sustaining the momentum of the global patient safety movement, as evidenced by the adoption of the WHA resolution (WHA72.6) “Global Action on Patient Safety” in May 2019, which enabled the first-ever World Patient Safety Day in September 2019.

Some of the world’s most prominent leaders in patient safety are presenting at the PSMF’s Summit this year, including Dr. Don Berwick, Senior Fellow at the Institute for Healthcare Improvements. In his keynote, Berwick will discuss how to ensure progress on improvements in patient safety remain at the forefront of the national conversation following last year’s recommendations to the US president in the PCAST report, “A Transformational Effort on Patient Safety.”

During the afternoon session, Dr. Craig Umscheid, Director of the Center for Quality Improvement and Patient Safety, Agency for Healthcare Research and Quality (AHRQ), will speak on AHRQ’s National Action Alliance for Patient and Workforce Safety, which takes a systems approach informed by safety self-assessments to improve patient and workforce safety across all healthcare delivery settings, with a goal of reducing harms by 50% from the pandemic peak in two years.

In her keynote, Dr. Michelle Schreiber, Director of Quality Measurement & Value Based Incentives Group, Center for Medicare and Medicaid Services (CMS), will detail the eight goals of CMS’s National Quality Strategy and outline CMS’s efforts to improve healthcare for all by promoting transparency and a safety culture through partnerships, while incentivizing zero harm.

The Summit’s first day will also include presentations from Dr. Diana Ramos, the Surgeon General of California; Dr. Peter Ziese, Head of Medical Innovation & Strategy at PHILIPS; Scott Hamilton Kennedy, an Academy Award-nominated documentary filmmaker; Dr. Evan Benjamin, Associate Professor of Medicine at Harvard Medical School; and Henrietta Hughes, the Patient Safety Commissioner for England.

Panel discussions will focus on advancements in using real-time data from electronic medical records, improving safety through systemwide collaboration, and the essential role hospital boards and the C-suite can play in fostering a culture of safety.

PATIENT SAFETY MOVEMENT FOUNDATION

In 2012, Joe Kiani founded the nonprofit Patient Safety Movement Foundation to eliminate preventable medical errors in hospitals. His team worked with patient safety experts from around the world to create Actionable Evidence-Based Practices that address top challenges. Hospitals can make a formal commitment to ZERO preventable deaths, and healthcare technology companies are asked to sign the Open Data Pledge to share their data so that predictive algorithms can be developed to identify errors before they become fatal. The PSMF was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240906604830/en/

Contacts

Patient Safety Movement Foundation
Irene Mulonni, irene@mulonni.com | (858) 859-7001

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye